Results 21 to 30 of about 681,398 (156)

Case Report: Identification of a novel NTRK3-AJUBA fusion co-existing with ETV6-NTRK3 fusion in papillary thyroid carcinoma

Frontiers in Oncology, 2023
NTRK fusions are validated oncogenic drivers of various adult and pediatric tumor types, including thyroid cancer, and serve as a therapeutic target. Recently, tropomyosin receptor kinase (TRK) inhibitors, such as entrectinib and larotrectinib, display ...
Qing-Xiang Yu, Wen-Jun Zhao, He-Yue Wang, Lei Zhang, Lan Qin, Lei Zhang, Jian-li Han   +6 more
doaj   +1 more source

NTRK-fusion associated sarcoma: Identification of two cases with a distinct perineurioma-like pattern

Human Pathology Reports, 2022
Neurotrophic receptor tyrosine kinase (NTRK) gene fusions are oncogenic drivers found in a few rare tumours. However, NTRK rearrangements are being increasingly identified in a range of soft tissue neoplasms. Recognition of NTRK fusion-driven sarcomas is
Vanessa Young, Daniel Wong, Max Yan, Fiona Maclean   +3 more
doaj   +1 more source

Primary Resistance to Larotrectinib in a Patient With Squamous NSCLC With Subclonal NTRK1 Fusion: Case Report

JTO Clinical and Research Reports, 2023
The NTRK genes encode the TRK proteins. NTRK fusions lead to constitutively active, ligand-independent downstream signaling. NTRK fusions are implicated in up to 1% of all solid tumors and 0.2% of NSCLC.
Mary C. Boulanger, MD, Jennifer S. Temel, MD, Mari Mino-Kenudson, MD, Lauren L. Ritterhouse, MD, PhD, Ibiayi Dagogo-Jack, MD   +4 more
doaj   +1 more source

Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China

Thoracic Cancer, 2022
Gene fusions can drive tumor development for multiple types of cancer. Currently, many drugs targeting gene fusions are being approved for clinical application.
Chunwei Xu, Lu Si, Wenxian Wang, Ziming Li, Zhengbo Song, Qian Wang, Aijun Liu, Jinpu Yu, Wenfeng Fang, Wenzhao Zhong, Zhijie Wang, Yongchang Zhang, Jingjing Liu, Shirong Zhang, Xiuyu Cai, Anwen Liu, Wen Li, Ping Zhan, Hongbing Liu, Tangfeng Lv, Liyun Miao, Lingfeng Min, Yu Chen, Jingping Yuan, Feng Wang, Zhansheng Jiang, Gen Lin, Xingxiang Pu, Rongbo Lin, Weifeng Liu, Chuangzhou Rao, Dongqing Lv, Zongyang Yu, Lei Lei, Xiaoyan Li, Chuanhao Tang, Chengzhi Zhou, Junping Zhang, Junli Xue, Hui Guo, Qian Chu, Rui Meng, Jingxun Wu, Rui Zhang, Xiao Hu, Jin Zhou, Zhengfei Zhu, Yongheng Li, Hong Qiu, Fan Xia, Yuanyuan Lu, Xiaofeng Chen, Rui Ge, Enyong Dai, Yu Han, Weiwei Pan, Jiancheng Luo, Hongtao Jia, Xiaowei Dong, Fei Pang, Kai Wang, Liping Wang, Youcai Zhu, Yanru Xie, Xinqin Lin, Jing Cai, Jia Wei, Fen Lan, Huijing Feng, Lin Wang, Yingying Du, Wang Yao, Xuefei Shi, Xiaomin Niu, Dongmei Yuan, Yanwen Yao, Jianhui Huang, Yinbin Zhang, Pingli Sun, Hong Wang, Mingxiang Ye, Dong Wang, Zhaofeng Wang, Bing Wan, Donglai Lv, Qing Wei, Jin Kang, Jiatao Zhang, Chao Zhang, Genhua Yu, Juanjuan Ou, Lin Shi, Zhongwu Li, Zhefeng Liu, Jing Liu, Nong Yang, Lin Wu, Huijuan Wang, Gu Jin, Liu Yang, Guansong Wang, Meiyu Fang, Yong Fang, Yuan Li, Xiaojia Wang, Yiping Zhang, Shenglin Ma, Biyun Wang, Xiaotian Zhang, Yong Song, Yuanzhi Lu   +110 more
doaj   +1 more source

Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo [PDF]

Cancer Biology and Therapy, 2015
Zhijie Li, Carol J. Thiele, Yuxin Tong
exaly   +2 more sources

Use of Diagnostic Algorithms for NTRK Fusion-Positive Tumors in Pathology Institutes in Switzerland

healthbook TIMES. Oncology Hematology, 2021
In May 2020, larotrectinib (Vitrakvi®) was approved as the first tumor-agnostic agent in Switzerland for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
Holger Moch, Gieri Cathomas, Milo Frattini, Wolfram Jochum, Erik Vassella, Laurence de Leval, Joachim Diebold, Christian Britschgi, Thomas McKee, Lukas Bubendorf   +9 more
doaj   +1 more source

NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability

Cancer Medicine, 2022
TRK fusions are rare but targetable mutations which occur across a wide variety of cancer types. We report the prevalence of approximately 0.7% for NTRK‐positive colorectal cancer (CRC) by genetically profiling 2519 colonic and rectal tumors.
Hui Wang, Zhi‐Wei Li, Qiuxiang Ou, Xue Wu, Misako Nagasaka, Yang Shao, Sai‐Hong Ignatius Ou, Yu Yang   +7 more
doaj   +1 more source

A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report

BMC Pulmonary Medicine, 2021
Background The identification of NTRK fusions in tumours has become critically important due to the actionable events predictive of response to TRK inhibitor.
Lei Zhang, Huanhuan Liu, Ye Tian, Huina Wang, Xueying Yang   +4 more
doaj   +1 more source

Targeted therapy for pediatric central nervous system tumors harboring mutagenic tropomyosin receptor kinases

Frontiers in Oncology, 2023
The family of the neurotrophic tyrosine kinase receptor (NTRK) gene encodes for members of the tropomyosin receptor kinase (TRK) family. Rearrangements involving NTRK1/2/3 are rare oncogenic factors reported with variable frequencies in an extensive ...
Selene Cipri, Francesco Fabozzi, Giada Del Baldo, Giada Del Baldo, Giuseppe Maria Milano, Luigi Boccuto, Andrea Carai, Angela Mastronuzzi   +7 more
doaj   +1 more source

Toward in vivo proof of binding of 18F-labeled inhibitor [18F]TRACK to peripheral tropomyosin receptor kinases

EJNMMI Research, 2022
Background Tropomyosin receptor kinases (TrkA, TrkB, TrkC) are a family of tyrosine kinases primarily expressed in neuronal cells of the brain. Identification of oncogenic alterations in Trk expression as a driver in multiple tumor types has increased ...
Melinda Wuest, Justin J. Bailey, Jennifer Dufour, Darryl Glubrecht, Vanessa Omana, Tom H. Johnston, Jonathan M. Brotchie, Ralf Schirrmacher   +7 more
doaj   +1 more source